Long-Acting Insulin Shows Promise Against Diabetes

Tuesday, 03 Dec 2013 12:46 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.
The treatment is one of several drugs Sanofi is betting on to defend its No.2 spot on the world's $42 billion diabetes market as its superstar product Lantus, the world's most prescribed insulin, will lose patent protection by 2015.
The long-acting insulin, known as U300, requires less frequent or lower dosing than Lantus and offers a more consistent insulin release. It is similar to Novo Nordisk's Tresiba (degludec), also in development.
Analysts expect Sanofi to seek regulatory approval for U300 in the United States and Europe next year and for the drug to reach global sales of $872 million by 2017, according to forecasts compiled by Thomson Reuters Cortellis.
The detailed Phase III results unveiled at the World Diabetes Congress in Melbourne showed U300 was better than Lantus at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin.
The drug also lowered the incidence of hypoglycemic events at any time of the day across the six-month study period.
U300 met its goal in three other Phase III clinical trials, showing similar blood sugar level control as Lantus in patients with type 2 diabetes not previously treated with insulin and uncontrolled on oral medication, as well as in patients with type 1 diabetes already treated with insulin.
Lantus, also known as insulin glargine, was developed in the 1990s and is currently Sanofi's top-selling drug. It reaped around 5 billion euros ($6.78 billion) in revenue last year.
Sanofi needs a successor for the drug and is also developing a pen-shaped device, known as LixiLan, that combines Lantus with Lyxumia, another diabetes treatment belonging to a class of drugs known as GLP-1 analogues.
The successful launch of both U300 and LixiLan could strengthen Sanofi against rival drugs such as Novo Nordisk's Tresiba (degludec) and IDegLira, a combination of Tresiba and Victoza.
Novo Nordisk, the global leader in diabetes, faced a setback earlier this year when the U.S. Food and Drug Administration asked for further clinical studies for Tresiba, delaying its potential launch on the world's largest pharmaceutical market until 2017 at the earliest.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Superbug Breakthrough: Gel Kills Antibiotic-Resistant Germs

Tuesday, 19 Aug 2014 16:46 PM

Scientists have made what they are describing as a breakthrough in the fight against resistant hospital superbugs. Resea . . .

Daughters Spend Twice as Much Time Caring for Elderly Parents as Sons

Tuesday, 19 Aug 2014 16:41 PM

Caregiving falls disproportionately on daughters of elderly parents, according to a new study presented at the American  . . .

Did Cocaine Abuse Give Robin Williams Parkinson's?

Tuesday, 19 Aug 2014 15:46 PM

When Robin Williams committed suicide last week, his publicist announced he had been suffering from severe depression. W . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved